Estimates of the overall number of patients with SLE, and patients on RTX, by country
| Country | Population | Patients with SLE * | SLE/10.000† | Patients with SLE on RTX‡ | Reference§ |
|---|---|---|---|---|---|
| Belgium | 10 839 905 | 5000 | 7.0 | 52 (1.0%) | PC |
| Denmark | 5 511 000 | 1000 | 2.7 | 10 (1.0%) | CRF35 |
| France | 61 538 322 | 22 500 | 5.5 | 360 (1.6%) | PC |
| Germany | 82 217 837 | 5000–30 000 | 0.9–5.5 | 150 (0.5%–3.0%) | CRF36 |
| Greece | 10 760 136 | 2800–7800 | 4–11 | 80–100 (1.0%–3.5%) | PC37 38 |
| Hungary | 10 045 000 | 3000–4500 | 4.5–6.8 | 15 (0.3%–0.5%) | CRF |
| Italy | 58 133 509 | 5500–30 000 | 1.4–7.8 | 70–150 (0.2%–2.7%) | CRF, PC |
| Spain | 46 030 109 | 15 000–40 000 | 4.9–13.2 | 150–450 (0.4%–3.0%) | CRF39 40 |
| Sweden | 9 471 174 | 3000–4000 | 4.8–6.4 | 80–135 (2%–4.5%) | CRF41 |
| The Netherlands | 16 594 107 | 3000–4500 | 2.7–4.1 | 16–120 (0.4%–4.0%) | CRF |
| Turkey | 73 723 000 | 27 700–34 000 | 4.6–7.0 | 40 (0.1%) | CRF42 |
| UK | 61 113 210 | 25 000 | 6.2 | 150–300 (0.6%–1.2%) | CRF27 43 44 |
| Total | 118 500–208 300 | 1173–1882 (0.6%–1.6%) | |||
| Remaining EEA countries¶ | |||||
| Austria** | 8 400 000 | 500–3000 | 0.9–5.5 | 15 (0.5%–3%) | |
| Bulgaria†† | 7 504 868 | 2200–3400 | 4.5–6.8 | 11 (0.3%–0.5%) | |
| Cyprus‡‡ | 854 000 | 225–600 | 4–11 | 6–8 (1.0%–3.6%) | |
| Czech Republic†† | 10 327 000 | 3100–4600 | 4.5–6.8 | 15 (0.3%–0.5%) | |
| Estonia†† | 1 338 000 | 400–600 | 4.5–6.8 | 2 (0.3%–0.5%) | |
| Finland§§ | 5 399 090 | 1700–2300 | 4.8–6.4 | 46–77 (2.0%–4.5%) | |
| Iceland§§ | 320 000 | 100–135 | 4.8–6.4 | 3–5 (2.2%–3.7%) | |
| Ireland¶¶ | 4 459 300 | 1800 | 6 | 11–22 (0.6%–1.2%) | 45 |
| Latvia†† | 2 263 000 | 700–1000 | 4.5–6.8 | 3 (0.3%–0.4%) | |
| Liechtenstein** | 33 717 | 2–12 | 0.9–5.5 | 0 | |
| Lithuania†† | 3 338 700 | 1000–1500 | 4.5–6.8 | 5 (0.3%–0.5%) | |
| Luxembourg** | 465 000 | 30–150 | 1–5 | 1 (0.7%–3.3%) | |
| Malta‡‡ | 417 608 | 110–300 | 4–11 | 3–4 (1.0%–3.6%) | |
| Norway§§ | 4 920 300 | 1600–2100 | 4.8–6.2 | 42–70 (2.1%–4.5%) | |
| Poland†† | 38 038 000 | 11 300–17 100 | 4.5–6.8 | 57 (0.3%–0.5%) | |
| Portugal*** | 10 605 870 | 4100–9200 | 5.9–13.2 | 35–104 (0.4%–2.5%) | |
| Romania†† | 21 462 186 | 6400–9600 | 4.5–6.8 | 32 (0.3%–0.5%) | |
| Slovakia†† | 5 411 000 | 1600–2400 | 4.5–6.8 | 8 (0.3%–0.5%) | |
| Slovenia†† | 2 010 347 | 600–900 | 4.5–6.8 | 3 (0.3%–0.5%) | |
| Total for countries under EMA jurisdiction | 573 545 295 | 155 967–268 997 | 4.1–7.1 | 1471–2324 (0.5%–1.5%) | |
*Data obtained from CRFs or journal references.
†Prevalence of SLE was calculated from the information provided in the CRFs and calculated from the adult population (adults=66% of the total population)) or journal references.
‡Figures obtained from the CRFs or journal references.
§Source of information is CRF, personal communication (PC) or journal reference.
¶Croatia is not included, as it was not a member of EU or EEA (European Economic Area) when data were collected.
**Assumed similar to Germany.
††Assumed similar to Hungary.
‡‡Assumed similar to Greece.
§§Assumed similar to Sweden.
¶¶Assumed similar to UK.
***Assumed similar to Spain.
CRF, case report forms; EMA, European Medicines Agency; RTX, rituximab; SLE, systemic lupus erythematosus.